Fluidigm and Visiopharm announce co-marketing programme
Fluidigm Corporation and Visiopharm today announced a new co-marketing programme, to offer Visiopharm® image analysis software for faster and more streamlined analysis of data acquired through Imaging Mass Cytometry™ (IMC™). The programme is the latest phase of an ongoing collaboration between the two companies.
Visiopharm is a world leader in image analysis, with a mission to transform pathology through AI-based image analysis and workflow standardization, offering solutions for digital pathology.
New software developed in collaboration with Visiopharm will enable native reading of data files from the Hyperion™ Imaging System, which uses IMC technology, imported into Visiopharm analysis tools. The new software will be launched at the 2021 Fluidigm IMC Summit on 21 October.
“As part of this latest milestone in our collaboration with Fluidigm, Visiopharm becomes the first company to provide third-party software that enables native reading of Imaging Mass Cytometry data files, with all metadata and imagery intact, eliminating the need for conversion to an intermediate format,” said Visiopharm CTO Johan Doré Hansen. “This simplifies the workflow, enabling faster analysis of cellular phenotypes and their interrelationships within the spatial context of the tissue microenvironment.
“With advanced capabilities for high-plex analysis and subsequent data mining, we believe Visiopharm is the partner of choice for the analysis of Imaging Mass Cytometry data files, and this enhancement will be yet another reason for researchers to choose IMC as the premier tool for uncovering meaningful new insights in health and disease.”
Globally, mass cytometry is utilized by 9 of the top 10 pharma companies. Mass cytometry technologies, including CyTOF®, Imaging Mass Cytometry and Maxpar® Direct™, have been used in more than 160 National Clinical Trials.
“The translational and clinical research testing markets have come to rely upon the Hyperion Imaging System for imaging solutions for biomarker discovery and drug development,” said Chris Linthwaite, President and CEO. “We are excited to partner with Visiopharm to further expand the ecosystem of Imaging Mass Cytometry data analysis tools, which provide valuable insights and advance health care decision making.”
Visiopharm® is a world leader in AI-driven digital pathology solutions. Visiopharm’s pioneering image analysis tools support thousands of scientists, pathologists, and image analysis experts in both academic institutions and the biopharmaceutical industry.
AI-based image analysis and tissue mining tools support research and drug development research worldwide, while their CE-IVD APPs support diagnostics. With the most advanced and sophisticated artificial intelligence and deep learning, they deliver tissue data mining tools, precision results, and workflows. Visiopharm was founded in 2001 and is privately owned. The company operates internationally with over 900 licenses and countless users in more than 40 countries. Company headquarters are in Denmark’s Medicon Valley, with further offices in Sweden, United Kingdom, Germany, Netherlands, and the United States.
Fluidigm (Nasdaq:FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com.
Fluidigm, the Fluidigm logo, CyTOF, Hyperion, Imaging Mass Cytometry, IMC, and Maxpar are trademarks and/or registered trademarks of Fluidigm Corporation or its affiliates in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.